250 related articles for article (PubMed ID: 35943866)
1. Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.
Pugashetti JV; Adegunsoye A; Wu Z; Lee CT; Srikrishnan A; Ghodrati S; Vo V; Renzoni EA; Wells AU; Garcia CK; Chua F; Newton CA; Molyneaux PL; Oldham JM
Am J Respir Crit Care Med; 2023 Jan; 207(1):69-76. PubMed ID: 35943866
[No Abstract] [Full Text] [Related]
2. Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease: A Multicenter Study.
Khor YH; Farooqi M; Hambly N; Johannson KA; Marcoux V; Fisher JH; Assayag D; Manganas H; Khalil N; Kolb M; Ryerson CJ;
Chest; 2023 Feb; 163(2):345-357. PubMed ID: 36089070
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting.
Kilpeläinen M; Hirvonen T; Perkonoja K; Hirsjärvi S
Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837481
[No Abstract] [Full Text] [Related]
4. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
[TBL] [Abstract][Full Text] [Related]
5. Lung function trajectory in progressive fibrosing interstitial lung disease.
Oldham JM; Lee CT; Wu Z; Bowman WS; Pugashetti JV; Dao N; Tonkin J; Seede H; Echt G; Adegunsoye A; Chua F; Maher TM; Garcia CK; Strek ME; Newton CA; Molyneaux PL
Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34737223
[TBL] [Abstract][Full Text] [Related]
6. Interstitial Lung Disease: A Review.
Maher TM
JAMA; 2024 May; 331(19):1655-1665. PubMed ID: 38648021
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of rheumatoid factor and anti-citrullinated peptides in fibrotic interstitial lung disease.
Zheng B; Donohoe K; Hambly N; Johannson KA; Assayag D; Fisher JH; Manganas H; Marcoux V; Khalil N; Kolb M; Ryerson CJ;
Respirology; 2022 Oct; 27(10):854-862. PubMed ID: 35652240
[TBL] [Abstract][Full Text] [Related]
8. Patterns of progression in non-IPF fibrotic interstitial lung disease.
Wells AU
Curr Opin Pulm Med; 2023 Sep; 29(5):459-464. PubMed ID: 37417940
[TBL] [Abstract][Full Text] [Related]
9. Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year.
Collins BF; Spiekerman CF; Shaw MA; Ho LA; Hayes J; Spada CA; Stamato CM; Raghu G
Chest; 2017 Jul; 152(1):103-112. PubMed ID: 28300570
[TBL] [Abstract][Full Text] [Related]
10. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
11. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases.
Adegunsoye A; Oldham JM; Bellam SK; Montner S; Churpek MM; Noth I; Vij R; Strek ME; Chung JH
Ann Am Thorac Soc; 2019 May; 16(5):580-588. PubMed ID: 30653927
[No Abstract] [Full Text] [Related]
12. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
13. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis.
Bowman WS; Newton CA; Linderholm AL; Neely ML; Pugashetti JV; Kaul B; Vo V; Echt GA; Leon W; Shah RJ; Huang Y; Garcia CK; Wolters PJ; Oldham JM
Lancet Respir Med; 2022 Jun; 10(6):593-602. PubMed ID: 35063079
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the diagnostic criteria for progressive pulmonary fibrosis in connective tissue disease related interstitial lung disease.
Lee J; Kim K; Jo YS
Respir Med; 2023 Jun; 212():107242. PubMed ID: 37031806
[TBL] [Abstract][Full Text] [Related]
15. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
[No Abstract] [Full Text] [Related]
16. Decreased Survival and Lung Function in Progressive Pulmonary Fibrosis.
Platenburg MGJP; van der Vis JJ; Grutters JC; van Moorsel CHM
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837496
[No Abstract] [Full Text] [Related]
17. Clinical effect of progressive pulmonary fibrosis on patients with connective tissue disease-associated interstitial lung disease: a single center retrospective cohort study.
Lee JK; Ahn Y; Noh HN; Lee SM; Yoo B; Lee CK; Kim YG; Hong S; Ahn SM; Kim HC
Clin Exp Med; 2023 Dec; 23(8):4797-4807. PubMed ID: 37831431
[TBL] [Abstract][Full Text] [Related]
18. Factors for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease.
Kim K; Lee J; Jo YS
Ther Adv Respir Dis; 2023; 17():17534666231212301. PubMed ID: 37991015
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype.
Takei R; Brown KK; Yamano Y; Kataoka K; Yokoyama T; Matsuda T; Kimura T; Suzuki A; Furukawa T; Fukuoka J; Johkoh T; Goto Y; Kondoh Y
Respirology; 2022 May; 27(5):333-340. PubMed ID: 35293077
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
